|
A new path to hope
Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:
1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms. 2. Long-term SPG stimulation for the treatment of vascular dementia patients.
 |
Focus: ISS
BrainsGate's product for the treatment of ischemic stroke and vascular dementia
read more |
 |
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death
read more |
|
October 13, 2009
ImpACT-24 at Central DuPage Hosital
National Investigational Trial for Emergency Stroke Care At CDH: One Illinois Hospital Tests New Device That May Reverse Brain Damage Up to 24 Hours After Stroke > full story
September 25, 2008
BrainsGate launches ImpACT-24
ImpACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window > full story
|